130
Participants
Start Date
May 24, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 30, 2028
SIM0500
Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
RECRUITING
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RECRUITING
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York
RECRUITING
Beijing Chaoyang Hospital Capital Medical University, Beijing
RECRUITING
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
RECRUITING
The First Affiliated Hospital Zhejiang University School of Medicine, Hanzhou
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Dana Farber Cancer institution, Boston
Lead Sponsor
Shanghai Xianxiang Medical Technology Co., Ltd.
INDUSTRY
Jiangsu Simcere Pharmaceutical Co., Ltd.
INDUSTRY